AACR Annual Meeting | Conference

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

April 29th 2025

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Dr Arbour on the Role of Zoldonrasib in KRAS G12D–Mutant NSCLC

April 28th 2025

Kathryn C. Arbour, MD, highlights the safety and early efficacy of zoldonrasib in patients with non–small cell lung cancer harboring KRAS G12D mutations.

Early ctDNA Clearance Is Associated With Response to Daraxonrasib in RAS-Mutant NSCLC

April 28th 2025

Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.

Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC

April 28th 2025

S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

April 28th 2025

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Tiragolumab Plus Atezolizumab Fails to Meet Survival End Points in Previously-Untreated, PD-L1–High NSCLC

April 28th 2025

First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer

April 28th 2025

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC

April 28th 2025

Treatment with 6.5 mg/kg of tegavivint was associated with primarily grade 1/2 TRAEs in patients with advanced hepatocellular carcinoma.

TMPRSS2-ERG Shows Distinct Molecular Landscape in TALAPRO-2 Population With mCRPC

April 28th 2025

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Zongertinib Yields Clinical Benefit in Previously Treated, HER2-Mutated, Advanced NSCLC

April 28th 2025

Zongertinib provided clinical benefit in previously treated advanced non–small cell lung cancer harboring HER2 mutations.

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

April 28th 2025

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

April 27th 2025

Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

April 10th 2024

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

April 10th 2024

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

April 10th 2024

The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.